SAB Biotherapeutics (SABS) EBIT Margin (2021 - 2025)
Historic EBIT Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 29287.09%.
- SAB Biotherapeutics' EBIT Margin changed N/A to 29287.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 69102.73%, marking a year-over-year increase of 725254000.0%. This contributed to the annual value of 3244.87% for FY2024, which is 15443200.0% down from last year.
- SAB Biotherapeutics' EBIT Margin amounted to 29287.09% in Q3 2025.
- Over the past 5 years, SAB Biotherapeutics' EBIT Margin peaked at 29287.09% during Q3 2025, and registered a low of 8726.26% during Q4 2024.
- In the last 5 years, SAB Biotherapeutics' EBIT Margin had a median value of 160.26% in 2022 and averaged 1654.83%.
- In the last 5 years, SAB Biotherapeutics' EBIT Margin tumbled by -74703700bps in 2023 and then surged by 190017700bps in 2025.
- Quarter analysis of 5 years shows SAB Biotherapeutics' EBIT Margin stood at 66.41% in 2021, then tumbled by -448bps to 363.74% in 2022, then plummeted by -1601bps to 6187.9% in 2023, then crashed by -41bps to 8726.26% in 2024, then soared by 436bps to 29287.09% in 2025.
- Its EBIT Margin stands at 29287.09% for Q3 2025, versus 15124.81% for Q2 2025 and 15484.95% for Q1 2025.